N/A N=90 pLatelEts And MigRaine iN patEnt foRamen Ovale
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
N/A N=459 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Migraine Disorders · Headache
Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
N/A N=100 A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Migraine Headache, Episodic
Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days
N/A N=20 Music Intervention on Migraine Headaches
Migraine Headache
Primary: Frequency of Migraine Attacks (Number of Days Per Month) — 8.45; 5.65 Number of migraine per months — p=0.012
N/A N=16,789 Chronic Migraine Epidemiology and Outcomes Study
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Phase 4 N=79 Treatment of Insomnia in Migraineurs
Insomnia · Migraine
Primary: Total Sleep Time — 5.4; 5.5; 6.3; 6.1 hours — p=0.33
N/A N=60 Bronx MBCT-Migraine
Migraine
Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027
Phase 4 N=220 Corticosteroids for Acute Migraine in the Emergency Department
Migraine
Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
N/A N=252 Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine Without Aura · Migraine With Aura
Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants
Phase 4 N=40 Ticagrelor Therapy for RefrACTORy Migraine Study
Migraine · Headache · Migraine Headache
Primary: Total Number of Responders — 17 Participants
Phase 2 N=40 Sumatriptan as Treatment for Post-traumatic Headache
Post-traumatic Headache
Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079
Phase 4 N=58 Intravenous Fluids in Benign Headaches Trial
Headache
Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score
Phase 3 N=157 MLD10 in the Prevention of Migraine in Adults
Migraine
Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days
N/A N=24 The Effect of Different Exercise Types on Migraine Frequency in Individuals With Migraine
Migraine · Chronic Migraine
Primary: Change in the Number of Days With Migraine (in Migraine Frequency) — 9.9; 12.4; 11.8; 6.3 days/month — p=0.001
N/A N=72 Introvision for Migraine and Headaches
Migraine · Chronic Migraine
Primary: Number of Headache Days Per Month — 10.6; 10.9 days per month — p=0.63
N/A N=230 PREMIUM Migraine Trial
Migraine Headaches · Patent Foramen Ovale
Primary: Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months. — 32; 38 percentage of…
Phase 3 N=50 Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
Migraine Headache
Primary: Verbal Pain Score at 60 Minutes — 4.5; 4.9 units on a scale (0-10)
Phase 4 N=70 Greater Occipital Nerve Block for Migraine Prophylaxis
Migraine Headache
Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…
Phase 2 N=387 A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
Migraine
Primary: Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 — 5.9; 6.2; 6.6; -0.9 Migraine attacks — p=0.1646
Phase 2 N=75 Staccato Prochlorperazine in Migraine (in Clinic)
Migraine Headache, With or Without Aura
Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants
Phase 2 N=16 Treatment for Migraine and Mood (Team-M)
Migraine · Depression
Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended
Phase 3 N=898 A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Migraine Disorders
Primary: Change From Baseline in Monthly Migraine Days (Weeks 1-12) — -4.3; -3.9; -4.1; -3.1 Migraine Days — p=0.0001
Phase 3 N=902 Phase 3 Study of MAP0004 in Adult Migraineurs
Migraine Disorders
Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
Phase 2 N=296 Continuous Treatment Study of Topiramate in Migraine Participants
Migraine
Primary: Number of Participants With Adverse Events — 110; 85; 79 Participants
Phase 3 N=34 Metformin for the Prevention of Episodic Migraine (MPEM)
Migraine
Primary: Headache Days — 23.64; 24.33 Days — p=0.83